NASDAQ: CYCCP - Cyclacel Pharmaceuticals, Inc.

Altı ay boyunca karlılık: -31.24%
Temettü getirisi: +2.99%
Sektör: Healthcare

Promosyon programı Cyclacel Pharmaceuticals, Inc.


Şirket hakkında Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.

daha fazla ayrıntı
It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

IPO date 2005-11-30
ISIN US23254L2079
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 2.99
Дивиденд ао 0.6
Сайт https://www.cyclacel.com
Цена ао 18.2
Günlük fiyat değişimi: 0% (6.47)
Haftalık fiyat değişimi: +6.94% (6.05)
Aylık fiyat değişimi: -4.15% (6.75)
3 ayda fiyat değişimi: -7.57% (7)
Altı ayda fiyat değişimi: -31.24% (9.41)
Yıllık fiyat değişimi: -60.36% (16.32)
3 yılda fiyat değişimi: -19.13% (8.0001)
5 yılda fiyat değişimi: +1 152.18% (0.5167)
10 yılda fiyat değişimi: 0% (6.47)
Yılbaşından bu yana fiyat değişimi: -13.73% (7.5)

Hafife alma

İsim Anlam Seviye
P/S 34.42 1
P/BV 23.81 1
P/E 0 0
EV/EBITDA -0.3672 0
Toplam: 3.5

Yeterlik

İsim Anlam Seviye
ROA, % -256.16 0
ROE, % -3715.82 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 2.99 7.48
DSI 0.8571 8.57
Toplam: 5.15

Görev

İsim Anlam Seviye
Debt/EBITDA -0.0012 10
Toplam: 10

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % -50.18 0
karlılık Ebitda, % 159.41 10
karlılık EPS, % 5522790.8 10
Toplam: 7.6

Kurumlar Hacim Paylaşmak, %
Sound Income Strategies, LLC 182 14.46
UBS Group AG 17 1.35



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Spiro George Rombotis President, CEO & Executive Director 612.47k 1959 (66 yıllar)
Mr. Paul McBarron Executive VP of Finance, CFO, COO, Secretary & Executive Director 321.61k 1961 (64 yıl)
Ms. Gill Christie Director of Human Resources N/A 1957 (68 yıllar)
Dr. Brian Schwartz M.D. Chief Medical Officer & Director 53k 1962 (63 yıl)
Grace Kim Investor Relations Executive N/A

Adres: United States, Berkeley Heights. NJ, 200 Connell Drive - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.cyclacel.com